A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Borges, Virginia F. [1 ]
Hamilton, Erika [2 ,3 ]
Yardley, Denise A. [2 ,3 ]
Chaves, Jorge [4 ]
Aucoin, Nathalie [5 ]
Ferrario, Cristiano [6 ]
Walker, Luke [7 ]
Krop, Ian [8 ]
机构：
[1] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol PLLC, Nashville, TN USA
[4] Northwest Med Specialties, Tacoma, WA USA
[5] Hop Cite de la Sante, Laval, PQ, Canada
[6] Jewish Gen Hosp, Montreal, PQ, Canada
[7] Oncothyreon Inc, Seattle, WA USA
[8] Dana Farber Canc Inst, Boston, MA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-15-08
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PATIENT-REPORTED OUTCOMES (PROS) IN HER2+METASTATIC BREAST CANCER (MBC) TREATED WITH T-DM1
    Agresta, S.
    Hurvitz, S.
    Lalla, D.
    Mathias, S.
    Burington, B.
    Sloan, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 345 - 345
  • [42] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
    Moulder, Stacy L.
    Borges, Virginia F.
    Baetz, Tara
    Mcspadden, Tessa
    Fernetich, Gina
    Murthy, Rashmi K.
    Chavira, Renae
    Guthrie, Kari
    Barrett, Emma
    Chia, Stephen K.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3529 - 3536
  • [44] Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
    Burris, Howard A., III
    Tibbitts, Jay
    Holden, Scott N.
    Sliwkowski, Mark X.
    Phillips, Gail D. Lewis
    CLINICAL BREAST CANCER, 2011, 11 (05) : 275 - 282
  • [45] PHASE I STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PATIENTS WITH NORMAL OR REDUCED HEPATIC FUNCTION.
    Agarwal, P.
    Li, C.
    Gibiansky, L.
    Dent, S.
    Goncalves, A.
    Nijem, I.
    Strasak, A.
    Lorusso, P.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S21 - S21
  • [46] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
  • [47] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Hunter, Francis W.
    Barker, Hilary R.
    Lipert, Barbara
    Rothe, Francoise
    Gebhart, Geraldine
    Piccart-Gebhart, Martine J.
    Sotiriou, Christos
    Jamieson, Stephen M. F.
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
  • [48] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Sarika Jain
    Ami N. Shah
    Cesar A. Santa-Maria
    Kalliopi Siziopikou
    Alfred Rademaker
    Irene Helenowski
    Massimo Cristofanilli
    William J. Gradishar
    Breast Cancer Research and Treatment, 2018, 171 : 371 - 381
  • [49] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Jain, Sarika
    Shah, Ami N.
    Santa-Maria, Cesar A.
    Siziopikou, Kalliopi
    Rademaker, Alfred
    Helenowski, Irene
    Cristofanilli, Massimo
    Gradishar, William J.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (02) : 371 - 381
  • [50] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
12345